Skip to main content
For US Residents Only

Vyleesi (bremelanotide injection) is the first and only FDA-approved as-needed treatment for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). It was approved by the FDA on June 21, 2019.

Do not use if you have:

See clinical trials info.

Book Virtual Appointment

with an independent healthcare provider

Book Now